|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis E virus infection in the liver transplant recipients:Clinical presentation and management显示文摘Hepatitis E virus(HEV) is an emerging pathogen and an increasingly recognized cause of graft hepatitis, especially in the post-orthotopic liver transplantation immunocompromised population. The exact incidence and prevalence of HEV infection in this population remains unclear but is certainly greater than historical estimates. Identifying acute HEV infection in this population is imperative for choosing the right course of management as it is very difficult to distinguish histologically from acute rejection on liver biopsy. Current suggested approach to manage acute HEV involves modifying immunosuppression, especially discontinuing calcineurin inhibitors which are the preferred immunosuppressive agents post-orthotopic liver transplantation. The addition of ribavirin monotherapy has shown promising success rates in clearing HEV infection and is used commonly in reported cases. | Avin Aggarwal Ryan B Perumpail Swetha Tummala Aijaz Ahmed | 2016 | World Journal of Hepatology2016，8，2： | 2 |
| 2 | Tumor necrosis factor-α: a mediator of focal ischemic brain injury显示文摘 | BARON FC AVIN B WHITE RF | 1997 | Stroke1997，28，6： | 1 |
| 3 | Treatment strategies for chronic hepatitis C prior to andfollowing liver transplantation显示文摘Hepatitis C virus(HCV)-related liver disease is the leading indication for liver transplantation(LT) worldwide. However, HCV is an independent predictor of lower survival following LT, and recurrence of HCV postLT is virtually universal. The historic standard of care during the interferon era of HCV therapy was expectant management-initiation of antiviral therapy in the setting of documented disease progression following LT. With the advent of new direct acting antiviral(DAA) therapies for HCV, the paradigm of expectant treatment for recurrent HCV infection post-LT is shifting. The safety, tolerability, and efficacy of DAAs, even among the sickest patients with advanced liver disease, enables treatment of HCV in the pre-transplant setting among LT waitlist registrants. Finally, emerging data are supportive of preemptive therapy with DAAs in liver transplant recipients as the preferred approach. Expectant management of HCV following LT can rarely be justified in the modern era of HCV therapy. | Ryan B Perumpail Thomas A Hahambis Avin Aggarwal Zobair M Younossi Aijaz Ahmed | 2016 | World Journal of Hepatology2016，8，1： | 1 |
| 4 | Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma 显示文摘 | Avin B Rund D Levin M | 2012 | Hematol Oncol2012，30，1： | 1 |
| 5 | The power of choice in ran- dom walks : an empirical study 显示文摘 | Avin C Krishnamachari B | 2008 | Computer Net- works2008，52，1： | 1 |
| 6 | Using hetero- geneity to enhance random walk-based queries 显示文摘 | Zuniga M Avin C Krishnamachari B | 2009 | Journal of Signal Processing Systems2009，57，3： | 1 |
| 7 | The Power of Choice in Random Walks:An Empirical Study显示文摘 | Avin C Krishnamachari B | 2008 | Computer Networks2008，52，1： | 1 |
| 8 | The power of choice in random walks:an empirical study显示文摘 | AVIN C KRISHNAMACHARI B | | 0，，01： | 1 |
| 9 | Impact of high-fat diet and vitamin D_3 supplementation on aortic stenosis establishment in waved-2 epidermal growth factor receptor mutant mice显示文摘Objective: The use of animal models of aortic stenosis(AS) remains essential to further elucidate its pathophysiology and to evaluate new therapeutic strategies. The waved-2 mouse AS model has been proposed;data have indicated that while aortic regurgitation(AR) is effectively induced, development of AS is rare.We aimed to evaluate the effect of high-fat diet(HFD) and vitamin D_3 supplementation in this model.Methods: HFD and subcutaneous vitamin D_3 injections were initiated at the age of 6 weeks until the age of 6(n = 16, 6-month treatment group) and 9(n = 11, 9-month treatment group) months. Twelve waved-2 mice without supplementation were used as control. Echocardiography was performed at 3, 6 and 9 months. Blood serum analysis(calcium, 1,25(OH)_2D_3 and cholesterol), histology and immunohistochemistry(CD-31, CD-68 and osteopontin) were evaluated at the end of the experiment(6 or 9 months).Results: Total cholesterol and 1,25(OH)_2D_3 were significantly increased relative to the control group. HFD and vitamin D_3 supplementation did result in improvements to the model, since AS was only detected in 6(15.3%) mice(2 in the 3 groups) and AR was developed in the remaining animals. Echocardiographic parameters, fibrosis, thickness, inflammation and valvular calcification, were not significantly different between the 6-month treatment and control groups. Similar results were also observed in the 9-month treatment group.Conclusion: These results suggest that HFD and vitamin D_3 supplementation have no effect in the waved-2 mouse model. This model essentially mimics AR and rarely AS. Further studies are needed to find a reliable animal model of AS. | Bérénice Colleville Nicolas Perzo Guillaume Avinée Ana?s Dumesnil Frederic Ziegler Paul Billoir Hélène Eltchaninoff Vincent Richard Eric Durand | 2019 | Journal of Integrative Medicine2019，17，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员